Neoadjuvant Toripalimab in Combination With Gemcitabine and Cisplatin Therapy in Local Advanced Bladder Cancer Subjects

This is a pre-surgical study involving subjects with local advanced bladder cancer, who are candidates for neoadjuvant therapy. It is a single-arm phase II portion.

Trial Details

NCT ID

NCT04861584

Phase

PHASE2

Sponsor

Zhujiang Hospital

Status

RECRUITING

Cancer Type

Bladder Cancer

Interventions

Neoadjuvant Toripalimab in Combination With Gemcitabine and Cisplatin

Locations (sample)

Guangzhou, Guangdong, China|23.11667,113.25

Key Eligibility Criteria

Patients between 18 and 75 years old on day of signing informed consent, regardless of gender;
ECOG score 0-1 points, expected survival time\> 6 months;
Pathologically confirmed locally advanced bladder urothelial carcinoma (cT2-T4a, N≤1, M0, tumor staging according to American Joint Committee on Ca…
Appropriate and plan for radical cystectomy;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Bladder Cancer Trials on Trialify →